NCT02302599

Mesenchymal Stem Cells to Treat Type 2 Diabetes

Efficacy and Safety of Umbilical-cord Mesenchymal Stem Cells in Chinese Adults With Type 2 Diabetes: a Single Center, Double-blind, Randomized, Placebo-controlled Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 103 (actual)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Umbilical cord mesenchymal stem cells indicate the therapeutic effects and safety on type 2 diabetes by characteristics of secretion and immune Immunomodulation.

Detailed description

Umbilical cord mesenchymal stem cells can improve insulin resistance of the target tissues, reduce the islet progressive damage, ease or regenerate of the islet beta cells and improve hyperglycemic state of diabetes by secreting a variety of cytokines. It can induce damaged alpha cells differentiate into beta cells in the islet transformation to realize the islet beta cells in situ regeneration by improving microenvironment of islet beta cells. Umbilical cord mesenchymal stem cells also have immunosuppressive effect, it can promote islet cell repair and regeneration by the inhibition of T cell mediated immune response to beta cells.

Conditions

• Type 2 Diabetes
• Mesenchymal Stem Cells

Interventions

Type	Name	Description
BIOLOGICAL	Umbilical cord mesenchymal stem cells	Infusion treatment
BIOLOGICAL	Controlled suspension liquid	Infusion treatment

Timeline

• Start date: 2013-01-01
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2014-11-27
• Last updated: 2021-02-03

Locations

1 site across 1 country: China